Are Non-Incretin Drugs Alternatives For Weight-Management?
Non-incretin obesity drugs are weight-management medications that do not target gut hormone incretin pathways, such as GLP-1 or GIP receptors. Instead, they use alternative mechanisms, such as blocking fat absorption or targeting different neurotransmitters in the brain to reduce appetite.
The term "non-incretin drug" refers to a drug, substance, or biological mechanism that lowers blood sugar or affects metabolism without using or mimicking the body's natural incretin hormone pathway.
Incretins are gastrointestinal polypeptide hormones that modulate insulin secretion from pancreatic beta cells. These hormones include glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) and are secreted from the upper gastrointestinal tract in response to meals. Incretins tell the pancreas to release more insulin when blood glucose is high.
Incretin-based drugs are GLP-1 receptor agonists, such as Ozempic or Mounjaro, that mimic glucagon-like hormones to control blood sugar and promote weight loss.
Non-incretin treatments or processes manage blood glucose through completely different pathways, for example, by working directly on the kidneys to flush out extra sugar (SGLT2 inhibitors) or helping body cells use existing insulin better, such as metformin or biguanides.
Common Non-Incretin Obesity Medications
These drugs are centrally acting and require monitoring for efficacy and side effects, such as nausea, headache, insomnia, or cardiovascular concerns.
| Drug | Structure |
| Small Molecules |
| Lorcaserin Lorcaserin acts on serotonin 2C receptors in the brain to reduce appetite and promote satiety, used alongside diet and exercise Lorcaserin functions as an appetite depressant and an anti-obesity agent. It is a benzazepine and an organochlorine compound. Lorcaserin is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. | 
195.69 g/mol |
| Naltrexone-Bupropion Naltrexone/bupropion is a combination pill of an addiction medication (naltrexone) and an antidepressant (bupropion) targeting brain areas controlling appetite and food cravings. Naltrexone is an opioid antagonist, and bupropion is an aminoketone atypical antidepressant. It is taken by mouth. Both component medications have individually demonstrated some evidence of effectiveness in promoting weight loss, and the combination has been shown to produce some synergistic effects on weight. | 
|
| Orlistat Orlistat is a gastrointestinal lipase inhibitor that works locally in the gut to block digestion and absorption of about one-third of dietary fat. Orlistat prevents the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet. | 
495.745 g·mol−1 |
| Phentermine Phentermine is a short-term appetite suppressant stimulating the central nervous system to lower hunger levels, typically prescribed for up to 12 weeks. Phentermine is a primary amine acting as a central nervous system stimulant, a central nervous system drug, a sympathomimetic agent, an adrenergic agent, a dopaminergic agent and an appetite depressant. Phentermine is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Stimulants substance. | 
149.23 g/mol |
| Phentermine-Topiramate Phentermine-Topiramate is provided as an oral combination capsule that merges phentermine with the seizure/migraine medication topiramate to increase feelings of fullness and make food taste less appealing. | 
488.6 g/mol |
| Peptides |
| BRP BRP administration triggers central FOS activation and acts independently of leptin, GLP-1 receptor and melanocortin 4 receptor. Using a computational drug discovery approach, Coassolo et al. (2025) systematically mapped more than 2,600 previously uncharacterized human proteolytic peptide fragments cleaved by prohormone convertases to identify novel bioactive peptides. This study identified a bioactive 12-mer peptide, BRINP2-related peptide (BRP). These results indicate that bioactive peptides can be identified in silico for testing in therapeutic applications. | THRILRRLFNLC 1541.90 g/mol |
| Setmelanotide, a cyclic peptide Setmelanotide is a melanocortin-4 receptor targeting agonist used primarily for rare, genetic (heritable/monogenic) forms of obesity such as Pro-opiomelanocortin (POMC) or Leptin receptor (LEPR) deficiency. Setmelanotide binds to and activates MC4 receptors in the paraventricular nucleus (PVN) of the hypothalamus and in the lateral hypothalamic area (LHA), areas involved in the regulation of appetite, and this action is thought to underlie its appetite suppressant effects. In addition to reducing appetite, setmelanotide increases resting energy expenditure in both obese animals and humans. | 
1117.32 g·mol−1
pdb|7PIU| RCXHXRWC |
| | |
| Sodium-Glucose Transport 2 (SGLT2) Inhibitors |
| Canagliflozin Canagliflozin is a hypoglycemic agent and a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise. | 
444.5 g/mol |
| Empagliflozin Empagliflozin is a sodium-glucose co-transporter 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor (SGLT2). The transporters are primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus. | 
450.9 g/mol |
| Ertugliflozin Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. | 
436.9 g/mol |
References
Coassolo L, B Danneskiold-Samsøe N, Nguyen Q, Wiggenhorn A, Zhao M, Wang DC, Toomer D, Lone J, Wei Y, Patel A, Liparulo I, Kavi D, Wat LW, Reghupaty SC, Kim JJ, Asemi T, Bielczyk-Maczynska E, Li VL, Moya-Garzon MD, Krentz NAJ, Stahl A, Chou DH, Luo L, Svensson KJ. Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide. Nature. 2025 May;641(8061):192-201. [PMC]
Deacon CF, Ahrén B. Physiology of incretins in health and disease. Rev Diabet Stud. 2011 Fall;8(3):293-306. [PMC]
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006 Mar;3(3):153-65. [Cell Metabolism]
Fredrick TW, Camilleri M, Acosta A. Pharmacotherapy for Obesity: Recent Updates. Clin Pharmacol. 2025 Sep 19;17:305-327. [PMC]
Lee S, Song H, Kwon Y. A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals (Basel). 2026 Jul 7;19(7):1047. [PMC}]
Padda IS, Mahtani AU, Parmarm M.; Sodium-Glucose Transport 2 (SGLT2) Inhibitors. [NIH-books]
“Bio-Synthesis is a business-to-business contract manufacturing and research organization. We do not sell GLP therapeutics directly to the public, dispense prescription medications, or provide medical treatment.
Please note: This article is intended for scientific and industry discussion only and should not be interpreted as medical advice. Patients should consult licensed healthcare professionals regarding GLP-based therapies.
Patients and medical doctors please contact pharmaceutical companies for more information”